ImmunityBio, Inc. Share Price & Technical Analysis
IBRX · $7.22 (-6.72%)
Healthcare / Biotechnology
$7.22
-6.72%
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cel…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
1% return in May, -5% avg return in past 3 year May month.
241% return in 2026, 12% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 210% | 56% | -20% | -7% | 1% | – | – | – | – | – | – | – | 241% |
| 25 | 35% | 0% | -6% | -17% | 8% | -7% | -4% | -4% | 9% | 0% | 0% | -17% | -3% |
| 24 | -32% | 34% | 10% | 51% | -19% | -3% | -19% | -23% | -5% | 41% | -4% | -48% | -17% |
| 23 | -27% | -37% | -25% | 56% | -3% | 4% | -21% | -27% | 6% | 82% | 16% | 35% | 58% |
| 22 | -5% | 13% | -16% | -36% | 6% | -3% | 3% | 5% | 25% | 8% | -2% | -7% | -9% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$8.32B
P/E ratio
—
52W high
$12.43
52W low
$1.95
Volume
1,79,39,227
Beta
0.07
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is ImmunityBio, Inc. share price today?
- ImmunityBio, Inc. (IBRX) last traded around $7.22 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IBRX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IBRX. Download the app for real-time alerts.
- How can I analyze ImmunityBio, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.